Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: Regen Eng Transl Med. 2023 Jan 26;9(3):424–430. doi: 10.1007/s40883-022-00292-9

Figure 2.

Figure 2.

ASC secretome as a potential combination therapy with iPN for neural applications. (a) ASC culture in modified medium (MM) with B27, b-FGF and retinoic acid caused a reproducible phenotypic shift from static (cuboidal) to activated (elongated) bodies. (b) ELISA results indicated little difference in BDNF secretion between batches (B1, B2, B3) or NB versus MM media. One significant difference, between B1 and B3, arose but with little change in BDNF production, *p-value<0.05. (c) VEGF ELISA results showed marked increase in the ASC group exposed to MM as compared to NB, ***p-value was <0.0001 for overall group ANOVA. (d) The PLGA encapsulation protocol was adapted to include all incubations on ice for biomolecules that may be temperature sensitive. Images of each protocol are shown and average particle size (n=30) for both are graphed.